ReviewIranian journal of pathology2026
Hepatic perivascular epithelioid cell tumor (PEComa): Clinicopathological Findings and Prognosis-A Systematic Review and Meta-Analysis.
Review in Iranian journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: Hepatic Perivascular epithelioid cell tumors (PEComas) are rare and can complicate diagnosis due to their low incidence, possible malignant potential and misdiagnosis as melanoma and hepatocellular carcinoma (HCC). The purpose of this systematic review and meta-analysis was to investigate the clinicopathological traits, diagnostic indicators, and prognostic implications associated with hepatic PEComas. Methods: We conducted a systematic literature search in PubMed, Web of Science, and Scopus using relevant keywords. Studies were included if they assessed clinicopathological findings or prognostic outcomes of hepatic PEComas. Data extraction was performed using a standardized sheet and data were pooled using RStudio. Results: The initial search retrieved 1,172 articles, from which 286 duplicates were removed. Ultimately, 15 studies met our eligibility criteria for inclusion in the meta-analysis. The mean patient age was 45.42 years. Misdiagnosis as HCC occurred in 18% of cases. The pooled malignancy rate was 8.6% with 6% of cases demonstrating tumor progression. Immunohistochemistry analysis revealed HMB-45 positivity in 98.8% (95% CI: 97% - 100%) and Smooth Muscle Actin positivity in 95.2% (95% CI: 81% - 98%) of cases. The mean tumor size was 67.1 mm (95% CI: 52.86 - 81.34), with 4.7% (95% CI: 3% - 8%) showing invasive features. Conclusion: Hepatic PEComas are predominantly benign but can pose diagnostic challenges due to their resemblance to HCC and melanoma. Despite generally favorable outcomes, long-term follow-up is crucial due to the risk of recurrence. Further prospective studies utilizing standardized diagnostic criteria are warranted to refine management strategies and identify prognostic indicators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.